Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis

Clinical Transplantation

Volumn 18, Issue 3, 2004, Pages 295-300

  Chan, Henry Lik Yuen ^a   Chui, Albert Ka Keung ^a   Lau, Wan Yee ^a   Chan, Francis Ka Leung ^a   Hui, Alex Yui ^a   Rao, Araga Ramesha Nitin ^a   Wong, John ^a   Lai, Eric Chun Hung ^a   Sung, Joseph Jao Yiu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatitis B virus; Lamivudine; Liver transplantation; YMDD mutants

Indexed keywords

ADEFOVIR DIPIVOXIL; AZATHIOPRINE; CYCLOSPORIN A; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; MORTALITY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROBABILITY; SURVIVAL RATE; VIRUS MUTANT; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS RESISTANCE;

EID: 2942576702     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00163.x     Document Type: Article

References (29)

1. Todo S, Demetris AJ, Van Thiel DH, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver diseases. Hepatology 1991: 13: 619.
2. Benner KG, Lee RG, Keee EB, Lopez RR, Sasake AW, Pinson CW. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992: 103: 1307.
3. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993: 329: 1842.
4. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996: 61: 1358.
5. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996: 24: 1327.
6. Dienstag JL, Schi ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999: 341: 1256.
7. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998: 339: 61.
8. Perrillo RP, Wright T, Rakela J et al. A Multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001: 22: 424.
9. Malkan G, Cattral MS, Humar A et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000: 69: 1403.
10. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000: 70: 809.
11. Lo CM, Cheung ST, Lai CL et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001: 233: 276.
12. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000: 46: 107.
13. Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2000: 47: 741.
14. Torre F, Campo N, Sinelli N, Brizzolara R, Andorno E. Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistent mutant. Longitudinal analysis. Transplantation 2000: 70: 1111.
15. Chan HLY, Chui AKK, Lau WY et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002: 68: 182.
16. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998: 27: 1711.
17. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replicative defective. Hepatology 1998: 27: 628.
18. Ono-Nita SK, Kato N, Shiratori Y et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999: 29: 939.
19. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996: 334: 693.
20. Ohkubo K, Kato Y, Kajiya Y et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002: 94: 2663.
21. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002: 347: 168.
22. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998: 28: 585.
23. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001: 34: 903.
24. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation - possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001: 34: 895.
25. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 2000: 6: 429.
26. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001: 49: 436.
27. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001: 49: 860.
28. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998: 1669.
29. Schiff E, Lai CL, Neuhaus P et al. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV) mutants. Hepatology 2002: 36: 371A.